PTC Therapeutics Inc (PTCT)
44.62
-0.25
(-0.56%)
USD |
NASDAQ |
Nov 12, 16:00
44.63
+0.01
(+0.02%)
After-Hours: 20:00
PTC Therapeutics Research and Development Expense (Quarterly): 161.41M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 161.41M |
| June 30, 2024 | 132.17M |
| March 31, 2024 | 116.13M |
| December 31, 2023 | 121.35M |
| September 30, 2023 | 164.21M |
| June 30, 2023 | 185.87M |
| March 31, 2023 | 195.12M |
| December 31, 2022 | 188.69M |
| September 30, 2022 | 165.46M |
| June 30, 2022 | 157.26M |
| March 31, 2022 | 140.08M |
| December 31, 2021 | 149.84M |
| September 30, 2021 | 130.84M |
| June 30, 2021 | 125.48M |
| March 31, 2021 | 134.51M |
| December 31, 2020 | 118.01M |
| September 30, 2020 | 93.00M |
| June 30, 2020 | 176.52M |
| March 31, 2020 | 90.11M |
| December 31, 2019 | 81.83M |
| September 30, 2019 | 63.08M |
| June 30, 2019 | 59.98M |
| March 31, 2019 | 52.57M |
| December 31, 2018 | 53.65M |
| September 30, 2018 | 54.37M |
| Date | Value |
|---|---|
| June 30, 2018 | 32.61M |
| March 31, 2018 | 31.36M |
| December 31, 2017 | 29.23M |
| September 30, 2017 | 30.02M |
| June 30, 2017 | 30.84M |
| March 31, 2017 | 27.36M |
| December 31, 2016 | 26.01M |
| September 30, 2016 | 31.40M |
| June 30, 2016 | 28.83M |
| March 31, 2016 | 31.40M |
| December 31, 2015 | 35.05M |
| September 30, 2015 | 30.64M |
| June 30, 2015 | 28.19M |
| March 31, 2015 | 27.94M |
| December 31, 2014 | 26.87M |
| September 30, 2014 | 18.76M |
| June 30, 2014 | 18.31M |
| March 31, 2014 | 15.89M |
| December 31, 2013 | 15.02M |
| September 30, 2013 | 13.89M |
| June 30, 2013 | 14.71M |
| March 31, 2013 | 11.26M |
| December 31, 2012 | 9.450M |
| September 30, 2012 | 10.47M |
| June 30, 2012 | 11.92M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
81.83M
Minimum
Dec 2019
195.12M
Maximum
Mar 2023
141.40M
Average
137.30M
Median
Research and Development Expense (Quarterly) Benchmarks
| Pfizer Inc | 2.598B |
| Vertex Pharmaceuticals Inc | 875.90M |
| BridgeBio Pharma Inc | 114.70M |
| Cassava Sciences Inc | 17.68M |
| Regeneron Pharmaceuticals Inc | 1.272B |